Immunitybio Operating Cycle from 2010 to 2026

IBRX Stock  USD 2.24  0.04  1.82%   
Immunitybio Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle will likely drop to 71.75 in 2026. During the period from 2010 to 2026, Immunitybio Operating Cycle regression line of annual values had r-squared of  0.0001 and arithmetic mean of  7,358. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
75.52
Current Value
71.75
Quarterly Volatility
22.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 M, Interest Expense of 159 M or Total Revenue of 17.8 M, as well as many indicators such as Price To Sales Ratio of 132, Dividend Yield of 0.0 or Days Sales Outstanding of 71.75. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
Build AI portfolio with Immunitybio Stock
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Immunitybio over the last few years. It is Immunitybio's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Very volatile
   Operating Cycle   
       Timeline  

Immunitybio Operating Cycle Regression Statistics

Arithmetic Mean7,358
Geometric Mean603.67
Coefficient Of Variation308.41
Mean Deviation10,921
Median231.17
Standard Deviation22,693
Sample Variance515M
Range94.4K
R-Value(0.01)
Mean Square Error549.3M
R-Squared0.0001
Significance0.97
Slope(45.71)
Total Sum of Squares8.2B

Immunitybio Operating Cycle History

2026 71.75
2025 75.52
2024 65.67
2023 1859.04
2022 3271.99
2020 520.93
2019 50.22

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 75.52  71.75 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.